Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17807789 | 0.83 | JAK2 (0.32) | — | |
| SCHEMBL17813469 | 0.80 | MEN1 (0.44) | MEN1RAB9AGFERKMT2ALRRK2 | |
| SCHEMBL18898720 | 0.72 | — | — | |
| SCHEMBL84926 | 0.70 | NNMT (0.33) | — | |
| SCHEMBL26141049 | 0.69 | GRM5 (0.35) | — | |
| SCHEMBL17807795 | 0.69 | MTOR (0.50) | — | |
| SCHEMBL15181316 | 0.67 | NNMT (0.30) | — | |
| SCHEMBL17807729 | 0.65 | PIK3R1 (0.34) | — | |
| SCHEMBL23507973 | 0.63 | JAK2 (0.31) | — | |
| SCHEMBL23889656 | 0.62 | MEN1 (0.33) | MEN1RAB9AGFERKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MEN1 3226/4885RAB9A 3185/4885GFER 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.